HeartWare International, Inc. (HTWR)

[cjgaddy]

10-3-11: Canaccord Reits. BUY on Heartware (PT=101); Positive HVAD Data at EACTS

”Canaccord Genuity Reiterates a 'Buy' on Heartware Intl (HTWR); Positive HVAD Data at EACTS”
Oct. 3, 2011 8:34AM EDT
• Canaccord Genuity reiterates a 'Buy' on Heartware Intl (NASDAQ: HTWR) price target of $101.
Canaccord analyst Jason R. Mills, said, "Updated HVAD data presented Sunday at EACTS in Lisbon showed device exchange (DE) rates via thrombus have fallen materially since the March change in aspirin regimen, which we think should assuage a major investor concern and act as a positive catalyst for HTWR shares. We believe these data will go a long way to mitigate bears’ fixation on the thrombus issue and put focus on other important considerations, many of which we think place HTWR in a favorable competitive position (survival, ease of implantation, infections, bleeding). What’s more, we remain bullish on the potential for LVAD market growth, which should behoove both HTWR and Thoratec."
"We continue to expect FDA approval of HVAD for bridge to transplant (BTT) in early 2012, preceded by a Panel meeting expected in Q4/11."
For more ratings news on Heartware Intl click here and for the rating history of Heartware Intl click here.
Shares of Heartware Intl closed at $64.41 yesterday, with a 52 week range of $53.40-$99.10.
http://www.streetinsider.com/Analyst+Comments/Canaccord+Genuity+Reiterates+a+Buy+on+Heartware+Intl+(HTWR)%3B+Positive+HVAD+Data+at+EACTS/6825205.html

= = = = = = = = = = = =
10-2-11: EACTS/Lisbon Breakout Session – Dr. Slaughter’s Slideshow
. . . http://investorshub.advfn.com/boards/read_msg.aspx?message_id=67611674

10-2-11/PR: HVAD/BTT Data Update given by Dr. Mark Slaughter (Univ.Louisville)
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=67606997

9-29-11 Canaccord reits BUY in prep. for Oct2 EACTS
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=67522757